Skip to main navigation
logo

Investor Contact

Our enduring purpose: to fundamentally improve the lives of patients with serious diseases in ways never before possible.

Investor Contact

Investor Contact

Martin Forrest
VP, Investor Relations & Corporate Communications

Questions for the Investor Relations Department can be submitted via email: ir@fiveprime.com

Print Page
RSS Feeds
E-Mail Alerts
Contact IR
Investor Relations
  • Home
  • Press Releases
  • Corporate Governance
    • Highlights
    • Management
    • Board of Directors
    • Committee Composition
    • Contact the Board
  • Events & Presentations
  • Financial Information
    • Financial Overview
    • SEC Filings
    • Annual Reports
    • Quarterly Results
  • Stock Information
    • Stock Quote & Chart
    • Historic Stock Lookup
    • Investment Calculator
    • Analyst Coverage
  • Investor Contact
  • Who We Are
    • About Us
    • Leadership
    • Board of Directors
    • Strategic Collaborations
    • Contact
  • Our Programs
    • Pipeline
    • Cabiralizumab
    • Bemarituzumab
    • FPA150
    • FPT155
    • TIM-3
    • Clinical Trials
    • Expanded Access
  • Our Science
    • Platform
    • Protein Library
    • Proprietary Screens
    • Publications
  • Join Our Team
    • Culture
    • Careers
  • Investors & Media
    • Press Releases
    • Corporate Governance
      • Highlights
      • Management
      • Board Of Directors
      • Committee Composition
      • Contact The Board
    • Events & Presentations
    • Financial Information
      • Financial Overview
      • SEC Filings
      • Annual Reports
      • Quarterly Results
    • Stock Information
      • Stock Quote & Chart
      • Historic Stock Lookup
      • Investment Calculator
      • Analyst Coverage
    • Investor Contact
  • News
  • Publications
  • Contact
  • LinkedIn
  • Twitter
  • Home
  • Who We Are
    • About Us
    • Leadership
    • Board of Directors
    • Strategic Collaborations
    • Contact
  • Our Programs
    • Pipeline
    • Cabiralizumab
    • Bemarituzumab
    • FPA150
    • FPT155
    • TIM-3
    • Clinical Trials
    • Expanded Access
  • Our Science
    • Platform
    • Protein Library
    • Proprietary Screens
    • Publications
  • Join Our Team
    • Culture
    • Careers
  • Investors & Media
    • Press Releases
    • Corporate Governance
      • Highlights
      • Management
      • Board Of Directors
      • Committee Composition
      • Contact The Board
    • Events & Presentations
    • Financial Information
      • Financial Overview
      • SEC Filings
      • Annual Reports
      • Quarterly Results
    • Stock Information
      • Stock Quote & Chart
      • Historic Stock Lookup
      • Investment Calculator
      • Analyst Coverage
    • Investor Contact
    • News
    • Publications
    • Contact
    • Linkedin
    • Twitter
    • Legal Notice
    • Privacy Policy

logo

© 2020 Five Prime Therapeutics, Inc. All rights reserved
  • Legal Notice
  • Privacy Policy
Website Design: Hane Chow, Inc.